Evidence map›Paper›PMID 35993765›Full record

ArticleMicrobiology spectrum2022

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring.

Tyler Brady, Tianhui Zhang, Kevin M Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L Roe, Kuishu Ren and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Different Fc scaffolds enhance the breadth ofFrontiers in immunology · 2025
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Tyler Brady *Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Tianhui Zhang *Data Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA.
Kevin M TuffyTranslational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Nantaporn HaskinsBiologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Qun DuBiologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Jia LinBiologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Gilad KaplanBiologics Engineering, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Steven NovickData Sciences and Quantitative Biology, AstraZeneca, Gaithersburg, Maryland, USA.
Tiffany L RoeTranslational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Kuishu RenVirology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Kim RosenthalVirology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Patrick M McTamneyVirology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Michael E AbramTranslational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.ORCID 0000-0002-6505-7281
Katie StreicherTranslational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Elizabeth J KellyTranslational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.ORCID 0000-0002-6988-8576
AstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants requires methods capable of quickly characterizing resistance to AZD7442. To support AZD7442 resistance monitoring, a biolayer interferometry (BLI) assay was developed to screen the binding of tixagevimab and cilgavimab to SARS-CoV-2 spike proteins to reduce the number of viral variants for neutralization susceptibility verification. Six spike variants were chosen to assess the assay's performance: four with decreased affinity for tixagevimab (F486S:D614G and F486W:D614G proteins) or cilgavimab (S494L:D614G and K444R:D614G proteins) and two reference proteins (wild-type HexaPro and D614G protein). Equilibrium dissociation constant (

Indexed as

COVID-19 Drug TreatmentSpike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralDrug CombinationsHumansImmunoglobulin FragmentsInterferometryRecombinant ProteinsReproducibility of ResultsSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, Viralcilgavimab and tixagevimab drug combinationDrug CombinationsImmunoglobulin FragmentsRecombinant ProteinsSpike Glycoprotein, Coronaviruscoronavirus disease 2019monoclonal antibodyreceptor binding domainsevere acute respiratory syndrome coronavirus 2spike protein

Identifiers

PMID35993765
PMCPMC9704045
OpenAlexW4292608643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.